Hot Money Rotation, Nothing Else -- As a long time investor, CTSO is in one of its best positions in the history of the company. Two days ago, a silly article came out comparing this money making company that uses filtration, with its existing and rapidly growing revenue streams, to startup biotechs with little or no revenues and no approved drugs. The SA writer misrepresented the true cope of CTSO. It was written by an amateur investor who believes in looking in a crystal ball to try to figure out if unapproved drug candidate will make a person a zillionaire years from now (but making it seem it could happen in the next few weeks. Good luck with that.) CTSO is the real deal and the product revenue numbers are the proof. This sell off will pass. Real investors, not dreamers, seeking real profits will support CTSO again, especially because 2020 revenues will likely rise 50%-100% and continue climbing from there.